1092569-10-2

Basic information

• Product Name: 5-bromo-3H-oxazolo[4,5-b]pyridin-2-one
• Synonyms: 5-BroMooxazolo[4,5-b]pyridin-2(3H)-one
• CAS NO: 1092569-10-2
• Molecular Formula: C₆H₃BrN₂O₂
• Molecular Weight: 215.004196
• Mol File: 1092569-10-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-bromo-3H-oxazolo[4,5-b]pyridin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-bromo-3H-oxazolo[4,5-b]pyridin-2-one(1092569-10-2)
• EPA Substance Registry System: 5-bromo-3H-oxazolo[4,5-b]pyridin-2-one(1092569-10-2)

Safety Data

• Hazardous Substances Data: 1092569-10-2(Hazardous Substances Data)

Upstream product

• 934758-27-7 2-amino-6-bromo-3-hydroxypyridine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1659-31-0 2,2'-dipyridyl carbonate 
• 443956-08-9 6-bromo-2-nitropyridin-3-ol 
• 530-62-1 1,1'-carbonyldiimidazole 
• 15128-82-2 3-hydroxy-2-nitropyridine 

Relevant articles and documents

COMPOUNDS AND THEIR METHODS OF USE

The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, abnormal late/persistent sodium current. Methods of treating a disease or condition relating to aberrant function of a sodium ion channel including Dravet syndrome or epilepsy are also provided herein.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS

The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).